SCHEMBL2778744

SCHEMBL2778744

CN1CCN(S(=O)(=O)O)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ATM Q13315 1/20 0.41
CYP1A2 P05177 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
USP2 O75604 1/20 0.39
TSHR P16473 2/20 0.38
HTT P42858 2/20 0.37
APOBEC3A P31941 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
MAPT P10636 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL9658965 0.97 POLB (0.42) POLBLMNAL3MBTL1KMT2AMEN1
Hydrochloric Acid SCHEMBL28095713 0.97 POLB (0.42) POLBLMNAL3MBTL1KMT2AMEN1
SCHEMBL1746338 0.85
Sulfuric Acid SCHEMBL8471322 0.82 CYP1A2 (0.48) POLBLMNAL3MBTL1KMT2AMEN1
SCHEMBL490219 0.74 CA1 (0.52) POLBLMNAL3MBTL1KMT2AMEN1
SCHEMBL1606347 0.74 L3MBTL1 (0.47) POLBLMNAL3MBTL1KMT2AMEN1
SCHEMBL25726143 0.74 POLB (0.33) POLBKMT2ATSHR
SCHEMBL48487 0.74 POLB (0.45) POLBLMNAL3MBTL1KMT2AMEN1
Sulfuric Acid SCHEMBL8471327 0.74 KMT2A (0.44) POLBLMNAL3MBTL1KMT2AMEN1
SCHEMBL1650338 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2328880-B1 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-10-31 EP claimed
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US claimed
CN-102149697-A 6-substituted benzoxazines as 5-HT-5A receptor antagonists HOFFMANN LA ROCHE 2011-08-10 CN claimed
WO-2010026110-A2 6-SUBSTITUTED BENZOXAZINES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 WO claimed
US-20100063037-A1 6-SUBSTITUTED BENZOXAZINES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 US claimed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US claimed
CN-1964946-A 2-propen-1-ones as HSP 70 inducers TORRENT PHARMACEUTICALS LTD (IN) 2007-05-16 CN claimed
EP-1748987-A2 2-PROPENE-1-ONES AS HSP 70 INDUCERS Torrent Pharmaceuticals Ltd (IN) 2007-02-07 EP claimed
WO-2005097746-A2 2-PROPENE-1-ONES AS HSP 70 INDUCERS TORRENT PHARMACEUTICALS LTD (IN) 2005-10-20 WO claimed
US-6046355-A TOLUENE-4-THIOSULFONIC ACID S-ESTERS AS CHEMICAL INTERMEDIATES FOR VIRICIDES AND ASPARTYL PROTEASE INHIBITORS; AIDS WARNER-LAMBERT COMPANY (US) 2000-04-04 US claimed
EP-0935597-A2 DIHYDROPYRONES WITH IMPROVED ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 1999-08-18 EP claimed
WO-1998019997-A2 DIHYDROPYRONES WITH IMPROVED ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 1998-05-14 WO claimed
WO-1997020823-A2 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 1997-06-12 WO claimed
WO-2023011446-A1 NOVEL SULFONAMIDE MENIN-MLL INTERACTION INHIBITOR, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 成都苑东生物制药股份有限公司 2023-02-09 WO disclosed
US-9233947-B2 Sulfamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2016-01-12 US disclosed
US-20140243329-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-08-28 US disclosed
WO-1998019997-A2 DIHYDROPYRONES WITH IMPROVED ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 1998-05-14 WO disclosed
WO-1997020823-A2 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 1997-06-12 WO disclosed
CN-1020104-C Process for preparing 3-propenyl cephem derivatives EISAI CO LTD (JP) 1993-03-17 CN disclosed
CN-87107610-A Process for the preparation of cephem derivatives and intermediates therefor 1988-06-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243329-A1 SULFAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 POLB 4606/4885LMNA 4330/4885L3MBTL1 4055/4885
US-20090227570-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2A POLB 4179/4885LMNA 2383/4885L3MBTL1 4395/4885
US-20100063037-A1 6-SUBSTITUTED BENZOXAZINES HTR5A, NPY5R, GABRA5 POLB 3665/4885LMNA 3682/4885L3MBTL1 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.